Details of the Drug

General Information of Drug (ID: DMJX2P4)

Drug Name
Fezakinumab
Synonyms Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
0S77U25XZ3
DrugBank ID
DB12344
TTD ID
D01AIN

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-22 (IL22) TTLDX4N IL22_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-22 (IL22) DTT IL22 3.69E-03 0.07 0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health.
2 Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.